RxDoctor Payments Data

Anthony Dominick, DO

Hematology & Oncology · Charleston, SCNPI 1477963676

Payments from drug & device makers

$8,452in general payments, 2019–2025

Across 51 payments — averaging $165.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$6K
  • Johnson & Johnson$622
  • Regeneron Healthcare Solutions, Inc.$278
  • Amgen$174
  • Daiichi Sankyo Inc.$165
  • Janssen Scientific Affairs, LLC$149
  • plus $884 from 18 others

What the payments were for

  • Consulting fees$6,18073%
  • Food & beverage$1,99824%
  • Education$2743%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,452 in reported general payments places this provider in the 50th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina

Medicare billing

Part B allowed, 2024
$88,060
Medicare patients
517
Services billed
940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib49$761,118
RevlimidLenalidomide50$713,038
CalquenceAcalabrutinib Maleate41$567,096
Lenalidomide35$508,900
BrukinsaZanubrutinib13$191,549
VenclextaVenetoclax18$181,880
SprycelDasatinib13$174,316
EliquisApixaban117$102,473
XareltoRivaroxaban44$47,491
ValacyclovirValacyclovir Hcl96$3,153
Hydroxyurea29$786
Anastrozole39$785
Acyclovir56$634
Dexamethasone16$389
Oxycodone Hcl32$342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$100$713,03850 claims
AstraZenecaCalquence$45$567,09641 claims
AbbVieVenclexta$129$181,88018 claims
E.r. Squibb & Sons, L.L.C.Sprycel$32$174,31613 claims
PfizerEliquis$23$102,473117 claims
Johnson & JohnsonXarelto$622$47,49144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 166 hematology & oncology providers in South Carolina.

Other hematology & oncology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →